Neoadjuvant chemotherapy combining a PD-1 inhibitor, apatinib, S-1, and oxaliplatin demonstrates significant efficacy for locally advanced gastric cancer (LAGC). In a study involving 130 patients, clinical complete response was achieved in 4.6%, with a total response rate of 71.5%. Notably, 96.1% underwent R0 resection, while 21.6% attained pathological complete response. The treatment was deemed safe, with no severe adverse events reported, underscoring the potential of this approach in improving surgical outcomes.
Journal Article by Tang Y, Dai L (…) Wang Q et 13 al. in Medicine (Baltimore)
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.